Clinical Trial Update: An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

An extended feasibility Phase I/II study evaluated methylenetetrahydrofolate (Arfolitixorin) with pemetrexed as neoadjuvant treatment in resectable rectal cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Arfolitixorin (arfolitixorin)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Isofol Medical AB | Conditions: Rectal Cancer | Phase 1, Phase 2 | Status: COMPLETED